Amgen Inc. is witnessing heightened market optimism following significant stock price upgrades, with UBS raising its target to $400, underscoring the company's robust revenue growth. Analysts point to promising developments, including the anticipated launch of therapies like Tezepelumab in the evolving eosinophilic esophagitis market, projected to reach USD 647 million by 2025. Despite challenges related to policy risks and patent expirations, assessments reveal Amgen is undervalued by nearly 44%, highlighting the potential for substantial gains as the company capitalizes on a solid pipeline and strategic partnerships.
“I think, you know, probably the biggest one that comes to mind is Amgen has a product in development called merited.”
“Church & Dwight Co., Inc. CHD, a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 8.5% over the past 12 weeks. Amgen Inc. AMGN has followed Church & Dwight with 8.2% returns.”
“On April 10, Morgan Stanley analyst Terence Flynn raised the firm’s price recommendation on Amgen Inc. (NASDAQ:AMGN) to $326 from $309. It reiterated an Equal Weight rating on the shares.”
“On April 8, Truist also boosted its price goal on Amgen to $325 from $319 and maintained a Hold rating.”
“It also increased the probability of success for MariTide, citing improved confidence in its commercial potential in obesity.”
“For Amgen specifically, Truist raised its longer-term penetration assumptions for Krystexxa, reflecting stronger patent protection through 2040.”
“Additionally, the expected launch of emerging therapies such as Tezepelumab (TEZSPIRE) (AstraZeneca and Amgen) will further propel the market growth.”
“Some of the key eosinophilic esophagitis therapies in clinical trials include Tezepelumab (TEZSPIRE)...These novel eosinophilic esophagitis therapies are anticipated to enter the eosinophilic esophagitis market in the forecast period and are expected to change the market.”
“The dynamics of the EoE market are expected to change in the coming years due to the launch of emerging therapies such as Tezepelumab (TEZSPIRE) (AstraZeneca and Amgen) and others.”
“The eosinophilic esophagitis market size in 2025 (US) is expected to reach USD 647 Million. Key Eosinophilic Esophagitis Companies include AstraZeneca, Amgen, Ellodi Pharmaceuticals, and others.”
“Eosinophilic Esophagitis Market Dynamics: Conjoint Analysis of Emerging Eosinophilic Esophagitis Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies.”
“Amgen's Blinatumomab is a pioneering bispecific T cell engager targeting CD19.”
